Composition
- Active ingredients
- PALBOCICLIB 100MG
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- PALBOCICLIB 100MG · CapsuleANDA212980-003 · Tentative approval
- PALBOCICLIB 125MG · CapsuleANDA212980-002 · Tentative approval
- PALBOCICLIB 125MG · CapsuleANDA213091-003 · Tentative approval
- PALBOCICLIB 75MG · CapsuleANDA213091-001 · Tentative approval
- PALBOCICLIB 100MG · CapsuleANDA213091-002 · Tentative approval
- PALBOCICLIB 100MG · TabletANDA215570-002 · Discontinued
- PALBOCICLIB 125MG · TabletANDA215570-003 · Discontinued
- PALBOCICLIB 75MG · TabletANDA215570-001 · Discontinued
- PALBOCICLIB 100MG · CapsuleThis page
- PALBOCICLIB 125MG · CapsuleANDA213086-003 · Tentative approval
- PALBOCICLIB 100MG · CapsuleANDA213107-002 · Tentative approval
- PALBOCICLIB 125MG · CapsuleANDA213107-003 · Tentative approval
- PALBOCICLIB 75MG · CapsuleANDA213107-001 · Tentative approval
At a glance
- Brand name
- Palbociclib
- Route
- Oral
- Dosage form
- Capsule
- Applicant
- Eugia Pharma Speclts
- Status
- Tentative approval
- FDA approval
- 7 Jul 2022
- Application
- ANDA213086-002